Research programme: c-Myc inhibitors - SUMO Biosciences
Latest Information Update: 12 Aug 2016
At a glance
- Originator SUMO Biosciences
- Mechanism of Action Proto oncogene protein c-myc inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 12 Aug 2016 Preclinical trials in Cancer in USA (unspecified route)